ClinicalTrials.gg
RecruitingNCT07702838Updated Jul 14, 2026

Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer

An interventional study of Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy. in Uterine Cervical Neoplasms, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Zhejiang Cancer Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital — 5 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Zhejiang Cancer Hospital.

Started
2026
with 1 other
No phase
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, this one is one of 2 that started in 2026, is one of 3 with no phase, and was the 10th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

5 of the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.

Read the detailed description

The primary objective of this study is to explore whether carbon ion radiotherapy combined with immunotherapy and chemotherapy can improve the 2-year progression-free survival (PFS) of patients with locally advanced cervical cancer (Stage IIB-IVA). The secondary objectives are to investigate whether this regimen can improve the 2-year overall survival (OS) of patients with locally advanced cervical cancer, and to evaluate the adverse events associated with carbon ion radiotherapy combined with immunotherapy and chemotherapy based on RTOG and CTCAE criteria.

03

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • Carbon Ion Radiotherapy
  • Immunotherapy
  • Chemotherapy
  • Survival Outcome
  • Uterine Cervical Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged ≥ 18 years at the time of signing the form.
  2. Histopathologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma).
  3. Stage IIB-IVA disease per the 2018 FIGO staging system.
  4. Presence of as defined by version 1.1.
  5. Patients reviewed by the carbon ion radiotherapy multidisciplinary team (MDT) with an indication for carbon ion radiotherapy.
  6. Patients voluntarily receiving carbon ion radiotherapy at Zhejiang Cancer Hospital and bearing all relevant treatment expenses.
  7. Complete clinical and imaging data available.
  8. Patients willing to participate in the trial and complete questionnaire surveys.
  9. Patients willing to participate in the trial and provide biospecimens, including cervical tissue, various body fluid specimens and tissue samples.
  10. Patients willing to attend regular standardised outpatient follow-up visits at our hospital.
  11. Eastern Cooperative 11. (ECOG) performance status (PS) score of 0-2.
  12. No prior history of surgery, radiotherapy or chemotherapy for cervical cancer.
  13. Adequate function of major vital organs (bone marrow, liver, kidney, etc.), with laboratory values meeting the following criteria within 1 week prior to treatment: (ANC) ≥ 1500/μL; count ≥ 100,000/μL; ≥ 9.0 g/dL (or ≥ 5.6 mmol/L); ≥ 50 mL/min; Total ≤ 1.5 × (ULN); if total bilirubin > 1.5 × ULN, direct bilirubin shall be ≤ ULN; (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (excluding patients receiving anticoagulant therapy within the therapeutic range).
  14. Estimated overall survival ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Presence of severe concomitant complications (e.g., uncontrolled cardiovascular disease, hypertension, diabetes mellitus, infection, active peptic ulcer, uncontrolled psychiatric disorders, etc.)
  2. Concurrent active second primary .
  3. Tumour invasion of the rectum (Stage IVA) or peritoneal (M1).
  4. Prior receipt of immunotherapy agents (including , anti-PD-L1, anti-CTLA-4, etc.).
  5. Prior radical surgery, radiotherapy, or systemic therapy (including agents) for cervical cancer. Note: Conisation of the cervix is permitted.
  6. Administration of any investigational drug within 4 weeks before the initiation of immunotherapy.
  7. Confirmed immunodeficiency or receipt of chronic systemic therapy (prednisone equivalent dose >10 mg/day) or other therapy within 7 days prior to immunotherapy.
  8. History of grade ≥3 severe reactions to immunotherapeutic agents.
  9. Active disease requiring systemic therapy within the past 2 years (replacement therapies such as thyroxine, insulin and physiological glucocorticoids are excluded).
  10. Prior history of non-infectious pneumonitis/interstitial lung disease requiring steroid treatment, or current active pneumonitis/interstitial lung disease.
  11. Active infection requiring systemic treatment.
  12. History of active (HBsAg positive) or active (detectable HCV RNA).
  13. Any disease, treatment, laboratory abnormality or other condition that, in the investigator's judgement, may confound study results, hinder full study participation or pose additional risks to the subject.
  14. Known psychiatric illness or substance abuse that may impair subject compliance; pregnant or breastfeeding females, or those planning conception/pregnancy during the study period (from screening to 120 days after the last study treatment).
  15. Previous allogeneic tissue or solid organ transplantation.
  16. History of infection.
  17. Metallic implants within the radiation field path that may compromise the accuracy of radiotherapy dose calculation.
  18. Subject requests withdrawal from the study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Immunotherapy Combined with Carbon Ion Radiotherapy and Concurrent Chemotherapy for Locally Advanced

    Immunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years. Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) given simultaneously with carbon ion external beam radiotherapy, for a total of 4 cycles. Radiotherapy: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional intracavitary brachytherapy.

    Radiation: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.

Interventions

  • RadiationCarbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.

    Immunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years. Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) is given simultaneously with carbon ion external beam radiotherapy for a total of 4 cycles.

    Also known as: Immunotherapy: Anti-PD-1 therapy, Chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    This endpoint is determined based on investigators' assessments per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). If disease progression cannot be confirmed by imaging according to RECIST 1.1, progressive disease (PD) histopathologically verified following carbon ion radiotherapy combined with three-dimensional brachytherapy, concurrent chemotherapy and immunotherapy shall serve as the criterion for progression determination.

    Time frame: At 2 years after the start of trial treatment

Secondary outcomes

  1. Overall survival (OS)

    To evaluate the 2-year overall survival rate of patients treated with carbon ion radiotherapy plus three-dimensional intracavitary brachytherapy combined with concurrent chemotherapy and immunotherapy. Death from any cause is defined as the endpoint event. Subjects who remain alive or are lost to follow-up at the data cut-off date will be treated as censored data.

    Time frame: At 2 years after the start of trial treatment

  2. Acute and late toxicities

    To evaluate acute and late toxicities of carbon ion radiotherapy plus three-dimensional intracavitary brachytherapy combined with concurrent chemotherapy and immunotherapy, graded per RTOG and CTCAE criteria.

    Time frame: Acute toxicities: AEs within 90 days of carbon ion radiotherapy start, graded per CTCAE & RTOG acute radiation morbidity criteria. Late toxicities: Radiation-associated tissue injuries new or worsening >90 days after the star radiotherapy initiation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Azzam AY, Ghozy S, Kallmes KM, Adusumilli G, Heit JJ, Hassan AE, Kadirvel R, Kallmes DF. Aspiration thrombectomy versus stent retriever thrombectomy alone for acute ischemic stroke: evaluating the overlapping meta-analyses. J Neurointerv Surg. 2023 Jan;15(1):34-38. doi: 10.1136/neurintsurg-2022-018849. Epub 2022 May 18. PubMed 35584912 ↗
  • Wakatsuki M, Kato S, Kiyohara H, Ohno T, Karasawa K, Tamaki T, Ando K, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Clinical trial of prophylactic extended-field carbon-ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508). PLoS One. 2015 May 20;10(5):e0127587. doi: 10.1371/journal.pone.0127587. eCollection 2015. PubMed 25993047 ↗
  • Wakatsuki M, Kato S, Ohno T, Karasawa K, Ando K, Kiyohara H, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Dose-escalation study of carbon ion radiotherapy for locally advanced squamous cell carcinoma of the uterine cervix (9902). Gynecol Oncol. 2014 Jan;132(1):87-92. doi: 10.1016/j.ygyno.2013.10.021. Epub 2013 Oct 29. PubMed 24183732 ↗
  • Jahangir Z, Bakillah A, Iqbal J. Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis. Diseases. 2018 Sep 17;6(3):82. doi: 10.3390/diseases6030082. PubMed 30227643 ↗
  • Elmanfi S, Ma X, Sintim HO, Kononen E, Syrjanen S, Gursoy UK. Quorum-sensing molecule dihydroxy-2,3-pentanedione and its analogs as regulators of epithelial integrity. J Periodontal Res. 2018 Jun;53(3):414-421. doi: 10.1111/jre.12528. Epub 2018 Jan 17. PubMed 29344966 ↗
  • Laserson U, Vigneault F, Gadala-Maria D, Yaari G, Uduman M, Vander Heiden JA, Kelton W, Taek Jung S, Liu Y, Laserson J, Chari R, Lee JH, Bachelet I, Hickey B, Lieberman-Aiden E, Hanczaruk B, Simen BB, Egholm M, Koller D, Georgiou G, Kleinstein SH, Church GM. High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4928-33. doi: 10.1073/pnas.1323862111. Epub 2014 Mar 17. PubMed 24639495 ↗
  • Zhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023. PubMed 38027108 ↗
  • Buizza G, Paganelli C, D'Ippolito E, Fontana G, Molinelli S, Preda L, Riva G, Iannalfi A, Valvo F, Orlandi E, Baroni G. Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma. Cancers (Basel). 2021 Jan 18;13(2):339. doi: 10.3390/cancers13020339. PubMed 33477723 ↗
  • Ma L, Li Y, Sakamoto Y, Xie L, Suzuki S, Yoshida Y, Sui L, Guo G, Wen J, Ren W, Kakimi K, Osada K, Takahashi A, Shimokawa T. Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody. Neoplasia. 2025 Feb;60:101099. doi: 10.1016/j.neo.2024.101099. Epub 2024 Dec 13. PubMed 39674115 ↗
  • Shiba S, Okonogi N, Kato S, Wakatsuki M, Kobayashi D, Kiyohara H, Ohno T, Karasawa K, Nakano T, Kamada T. Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers. Anticancer Res. 2017 Oct;37(10):5577-5583. doi: 10.21873/anticanres.11991. PubMed 28982873 ↗
  • Okonogi N, Ando K, Murata K, Wakatsuki M, Noda SE, Irie D, Tsuji H, Shozu M, Ohno T. Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. Cancers (Basel). 2021 May 31;13(11):2713. doi: 10.3390/cancers13112713. PubMed 34072676 ↗
  • Wang X, Chen X, Li G, Han X, Gao T, Liu W, Tang X. Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review. Front Oncol. 2021 Jul 5;11:708724. doi: 10.3389/fonc.2021.708724. eCollection 2021. PubMed 34290989 ↗
  • Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel). 2020 Oct 17;12(10):3022. doi: 10.3390/cancers12103022. PubMed 33080914 ↗
  • Reinhardt JM, Christensen GE, Hoffman EA, Ding K, Cao K. Registration-derived estimates of local lung expansion as surrogates for regional ventilation. Inf Process Med Imaging. 2007;20:763-74. doi: 10.1007/978-3-540-73273-0_63. PubMed 17633746 ↗
  • Paskett ED. Breast cancer-related lymphedema: attention to a significant problem resulting from cancer diagnosis. J Clin Oncol. 2008 Dec 10;26(35):5666-7. doi: 10.1200/JCO.2008.19.0850. Epub 2008 Nov 10. No abstract available. PubMed 19001317 ↗
  • Nixon PL, Rangan A, Kim YG, Rich A, Hoffman DW, Hennig M, Giedroc DP. Solution structure of a luteoviral P1-P2 frameshifting mRNA pseudoknot. J Mol Biol. 2002 Sep 20;322(3):621-33. doi: 10.1016/s0022-2836(02)00779-9. PubMed 12225754 ↗
  • Costabile M, Hii CS, Robinson BS, Rathjen DA, Pitt M, Easton C, Miller RC, Poulos A, Murray AW, Ferrante A. A novel long chain polyunsaturated fatty acid, beta-Oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed-type hypersensitivity, and carrageenan-induced paw reaction and selectively targets intracellular signals. J Immunol. 2001 Oct 1;167(7):3980-7. doi: 10.4049/jimmunol.167.7.3980. PubMed 11564817 ↗
  • Haeker M, Wu X, Abramoff M, Kardon R, Sonka M. Incorporation of regional information in optimal 3-D graph search with application for intraretinal layer segmentation of optical coherence tomography images. Inf Process Med Imaging. 2007;20:607-18. doi: 10.1007/978-3-540-73273-0_50. PubMed 17633733 ↗
  • Anand KJ, Barton BA, McIntosh N, Lagercrantz H, Pelausa E, Young TE, Vasa R. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates. Arch Pediatr Adolesc Med. 1999 Apr;153(4):331-8. doi: 10.1001/archpedi.153.4.331. PubMed 10201714 ↗
  • Thomson DP, Brown R, Dunn K, Scanlan E. Effect of a ground critical care transport service on air medical helicopter utilization. Prehosp Emerg Care. 1999 Apr-Jun;3(2):136-9. doi: 10.1080/10903129908958922. PubMed 10225647 ↗
  • Xia KQ, Sun C, Zhou SQ. Particle image velocimetry measurement of the velocity field in turbulent thermal convection. Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Dec;68(6 Pt 2):066303. doi: 10.1103/PhysRevE.68.066303. Epub 2003 Dec 17. PubMed 14754311 ↗
  • Yawn BP. Vaccines and physician behavior. Arch Pediatr Adolesc Med. 1999 Apr;153(4):326-7. doi: 10.1001/archpedi.153.4.326. No abstract available. PubMed 10201713 ↗
  • Kazdin AE, Wassell G. Therapeutic changes in children, parents, and families resulting from treatment of children with conduct problems. J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):414-20. doi: 10.1097/00004583-200004000-00009. PubMed 10761342 ↗
  • Latz S, Wolf AW, Lozoff B. Cosleeping in context: sleep practices and problems in young children in Japan and the United States. Arch Pediatr Adolesc Med. 1999 Apr;153(4):339-46. doi: 10.1001/archpedi.153.4.339. PubMed 10201715 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly due to limitations of institutional data repository, privacy protection of cervical cancer patients, and lack of dedicated funding for data curation and management.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2029, 41 months later.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 41 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 14, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07702838
Responsible party
Yin ZhuoMin (Professor, Zhejiang Cancer Hospital) — Principal investigator
First posted
Jul 14, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 14, 2026

Study contacts

Zhuomin Yin, MD
Contact
yinzm@zjcc.org.cn
Hanmei Lou, MD
study chair · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion